Gil Addo, SVP, Specialty Care Solutions | CVS Health and Co-founder of RubiconMD, a wholly-owned subsidiary of CVS Health. RubiconMD’s digital health platform empowers primary care clinicians with access to virtual specialist support to improve patient care. Founded in 2013, RubiconMD serves primary care clinicians across 37 states. The Huffington Post named RubiconMD one of the “Five Companies Defining the Future of Healthcare” and, in 2020, AllianceBernstein ranked RubiconMD number 12 on its list of the top 25 private companies disrupting healthcare. The company raised over $40 million in capital from top tier investment firms and in 2021 was acquired by Oak Street Health for $190 million. Prior to founding RubiconMD, Gil was a Consultant at Putnam Associates, a pharma strategy consultancy, where he designed payer and market access strategies for fortune 500 clients. He previously held strategy and business development roles at Xerox, Cubist (acquired by Merck), and two early stage healthcare ventures. Gil has appeared in Inc, Forbes, CNBC, Fortune and Entrepreneur Magazine. He’s been named one of Forbes’ “30 Under 30” in healthcare, Crains New York Business 40 Under 40 and Business Insider’s 30 under 40 in healthcare. In 2020, Crains New York named Gil to its list of the Most Notable in Health Care and in 2017 he received their Heritage Healthcare Innovator of the Year award. He holds a BS in Economics and Biomedical Engineering from Yale and an MBA from Harvard.

Dr. Ajayi is a Board-certified Family Medicine physician and CEO of Cityblock Health, a value-based provider for Medicaid and dually eligible beneficiaries. Prior to Cityblock, she served as Chief Medical Officer of Commonwealth Care Alliance, an integrated health plan and care delivery system for Medicare and Medicaid beneficiaries. Dr. Ajayi serves on the Board of Directors of Evolent Health and is a co-founder of Coalition Partners. She’s an Aspen Institute Henry Crown Fellow and a member of the National Academy of Medicine. She’s been named to Inc.’s Female Founders 500 list, TIME100 Next, Modern Healthcare’s Top Women Leaders in Healthcare, and STATUS List.

John Brownstein, Ph.D, is a Professor of Pediatrics at Harvard Medical School as well as SVP and Chief Innovation Officer of Boston Children’s Hospital. He directs both the Computational Epidemiology Laboratory and the Innovation and Digital Health Accelerator. Trained as an epidemiologist at Yale University, his research has been instrumental in facilitating the control and prevention of disease, improving public health practice, and engaging the public in health issues. As a pioneer in computational epidemiology, Dr. Brownstein's research is recognized for its translational impact, particularly through the development and application of Artificial Intelligence (AI), data mining, and citizen science. His innovative platforms, such as Vaccines.gov, Global.health, and HealthMap, serve millions annually and have received recognition from the National Library of Congress and the Smithsonian. His research was pivotal in the early detection and response to major disease outbreaks, including H1N1 in 2009, Ebola in 2014, Zika in 2015 and COVID in 2019. Dr. Brownstein's contributions extend beyond academia into advisory roles for agencies including HHS, DHS, FDA, DOD, CDC, WHO, and the White House. As Chief Innovation Officer, his efforts have catalyzed the launch of dozens of new startups and unique partnerships with companies like Google, Amazon, Apple, Uber, Instacart, Microsoft, and OpenAI. He also plays a leading role in shaping the hospital’s comprehensive digital strategy, including the integration of AI to improve patient care. Dr Brownstein has been honored with the Presidential Early Career Award for Scientists and Engineers, the highest honor bestowed by the United States government to outstanding scientists, the Lagrange Prize for international achievements in complexity sciences and an Emmy for his contributions to medical reporting for ABC News during the covid-19 pandemic. Dr. Brownstein is co-founder of digital health companies Epidemico and Circulation and an ABC Medical News Contributor. He has authored over 300 peer-reviewed articles on epidemiology and public health.

Sree Chaguturu, MD, is Executive Vice President, President of Healthcare Delivery, of CVS Health. Previously, he was CMO of CVS Caremark, where he focused on enhancing the quality of services provided to millions of its members and patients, while also contributing to the overall mission of CVS Health. Prior to CVS, Sree was Chief Population Health Officer at Partners HealthCare. In this role, he led the system’s accountable care organization, one of the largest in the nation serving over 600,000 lives. Previously, he was a health care consultant at McKinsey and Company. Dr. Chaguturu is also a practicing internal medicine physician at Massachusetts General Hospital and a Lecturer at Harvard Medical School. His articles have appeared in publications such as the New England Journal of Medicine, JAMA, and Health Affairs. Dr. Chaguturu received his BA degree in biology from Brown University and his Doctor of Medicine degree from Brown University Medical School. He completed his internal medicine and primary care training at Massachusetts General Hospital.

Ian is a Partner at Flare Capital, led the firm’s investment into Knownwell and was an essential part of the firm’s investments in Inbound Health and RightMove, where he serves as a board member, as well as Cayaba Care, and Oshi Health. Additionally, Ian led the firm’s Flare Scholar Ventures investments in Adni, EarlyBird Education, Narrable, and Vincere Health. Prior to joining Flare Capital, Ian served as a Senior Vice President and a founding member of CareAllies, Cigna’s family of multi-payer provider services, population health management, and home-based care businesses. In that capacity, he was responsible for developing new technology-enabled services, evolving existing solutions and service lines, and providing ongoing product management across CareAllies’ businesses. In addition, he was also responsible for developing inorganic strategies for CareAllies since its inception. Before launching CareAllies, Ian held a leadership position with Cigna’s US Strategic Operations team. Ian was a co-founder of several start-ups, including XcelDx, which ultimately partnered with Scanwell Health, a smartphone-enabled diagnostics company backed by Y-Combinator, Founders Fund, DCM, Version One, and Mayfield. He focused his efforts on product development and served as an advisor to the company. Scanwell was acquired by BD (Becton, Dickinson and Company) in 2021. He also worked for Becton, Dickinson & Company, where he led new product innovation and development. He continues to actively advise and mentor a number of innovative healthcare start-ups. He started his career at McKinsey & Company and spent five years advising healthcare clients globally. Ian serves as an advisor and board member of various organizations. He is currently a member of the Board of Directors at The New England Venture Capital Association and Harvard Business School Healthcare Alumni Association, where he also served as the 2021 Annual Conference Co-Chair. Additionally, Ian serves as an Industry Advisor at Cornell Tech’s The Precision Behavioral Health Initiative. Ian has a Bachelor of Science degree in biological engineering from Cornell University, where he graduated with honors and was a Cornell Presidential Research Scholar. He also holds an MBA from Harvard Business School.

Geoff is CEO of Noom. Within two years of joining, he drove the launch of Noom Med product lines—now the majority of revenue—and established Noom’s mission: to empower everyone, everywhere to live better longer—every day. At Noom, he is leading the convergence of diagnostics, lifestyle support, and convenient care. He launched AI screening tools (Face Scan, Future Me); expanded Noom’s free tier to broaden access; and built the industry’s most advanced GLP-1 Companion, to improve outcomes and drive lasting health gains Geoff is also a serial entrepreneur and long-time public company CEO. Geoff co-founded The Meet Group (NASDAQ) and served as CEO (2013–2023), leading its $500M sale in 2020 and scaling live-streaming/creator economy revenue to $200M+ annualized. He’s an Ernst & Young Entrepreneur of the Year Award Winner (Philadelphia). He holds a Harvard BA (Economics) and is pursuing an MS in Nutrition Science at Tufts.

Jacob Donoghue, MD, PhD, is the Co-Founder and CEO of Beacon Biosignals, founded in 2019 with the mission of decoding sleep to advance brain health. He leads the company’s efforts to transform how neurological, psychiatric, and sleep disorders are diagnosed and treated using AI-powered sleep EEG analytics. Under his leadership, Beacon has built a platform that combines FDA-cleared wearable EEG devices with advanced analytics to identify digital neurobiomarkers, supporting precision medicine in clinical trials and diagnostics. Dr. Donoghue received his MD from Harvard Medical School and PhD in neuroscience from MIT, where his research focused on how neuroactive compounds modulate brain network activity. His scientific work spans neurophysiology, neuropharmacology, and machine learning for neural signal analysis.

Caitlin Donovan is a highly recognized builder and operator in the healthcare space who shares our commitment to make health assurance a reality – where healthcare is more accessible, proactive and affordable for all. Caitlin was most recently the Global Head of Uber Health, Uber’s business unit focused on creating a first-of-its-kind supplemental benefit platform offering non-emergency transportation, prescription delivery, grocery, and over the counter item benefits to Medicare Advantage, Managed Medicaid, and Commercial populations. During her 3 year tenure there, she substantially scaled the business, reimagining how technology intersects with healthcare. Prior to Uber Health, she served as Chief Operating Officer and VP Operations in a variety of businesses focused on medical transportation, home health, multi-clinic providers and post-acute care. Early in her career, she worked as an investor at Bain Capital and at Summit Partners where she built a strong understanding of finance. She earned her bachelor's degree in Economics from Harvard University and lives in Dover, Massachusetts with her husband and two boys.

As an undergraduate at Brown University, Robbie Felton co-founded IntusCare to provide the specialized technology infrastructure required to help older adults age healthily and independently at home. Now serving as CEO, Felton has led the company to secure over $30 million in funding while partnering with more than 100 PACE organizations nationwide to bridge the gap between complex medical needs and community-based living. For his leadership in digital health, Felton has been honored by Forbes 30 Under 30, Modern Healthcare 40 Under 40, and as a Rock Health Top 50 in Digital Health "System Disruptor."

Katerina is Investment Director at Philips Ventures, a corporate venture arm of Philips. She is focused on digital health and health tech investments aligned with Philips’ mission to improve health and well-being through meaningful innovation. Katerina's passion lies in scaling tech-innovative businesses, driving impactful M&A, and supporting visionary entrepreneurs, often in dynamic and challenging markets. She works closely with early- and growth-stage portfolio companies, guiding them through commercialization and scaling operations. She currently serves on the boards of Orbita.AI, MOVN Health, Babyscripts, PreciseDx, and Noninvasix, and have supported successful exits, most recently Carevive/Health Catalyst. Katerina has earned her MBA from MIT Sloan. She is a mentor and judge at MassChallenge, an organizing committee member for the MIT Sloan CFO Summit, an active participant in AI Innovators Community (AIC), advisor, and a frequent speaker at conferences including DHIS, LSX, LSI.

Dave has devoted his career to building and leading innovative businesses, including the last 16 years with companies transforming the way healthcare is delivered. He joined Rubicon Founders in 2024, and leads Rubicon's Operating Partner team, helping our portfolio company leaders navigate the exciting stages of growth. Prior to Rubicon, Dave led the finance function at several investor-backed businesses, most notably as the CFO at Iora Health, a value based primary care provider that ultimately sold to One Medical (now part of Amazon). Dave also served as CFO of Verily's Health Platform division, and as CFO at Calibrate, a telemedicine platform for people with obesity. Earlier in his career, Dave was a member of Cerberus Capital's Operations and Advisory Company, partnering with a wide range of portfolio companies on value creation initiatives. Dave graduated from Tufts University and Harvard Business School, and he and his wife, Amy, have four children.

Liana Guzmán is the CEO of FOLX Health, a category-defining digital healthcare provider delivering affirming care to the LGBTQIA+ community nationwide. With nearly 20 years of experience leading disruptive companies in regulated industries, she has helped modernize legacy systems and set new standards for innovation and impact across healthcare, fintech, and education. Named to Fast Company’s Queer 50 and a Henry Crown Fellow, she also serves on the boards of GLAAD and The Elizabeth Park Conservancy. Born in Puerto Rico, she’s a proud mom, wife, and advocate for equity and systems change.

Ellen Herlacher is a healthcare investor with a deep background in investment management, healthcare operations, and corporate strategy. As Partner at LRVHealth, Ellen co-leads the firm’s research and investments in new care delivery, behavioral health, workforce transformation, and government sponsored payers. In this role, she led LRVHealth’s investments in Diana Health, a reimagined maternity care company, and Cortica, a physician-led, whole-child, value-based autism services company. She also supports the firm’s investments in Reimagine Care, Huddle Up, Greater Good Health, and Season. Before joining LRVHealth in 2020, Ellen was director of Tufts Health Ventures, the corporate development and corporate investment arm of Tufts Health Plan (now Point32 Health). Prior to joining Tufts, she held management roles at athenahealth and investment and consulting roles at Goldman Sachs and Bain & Company. Ellen earned a B.A. from Cornell University and M.B.A. from Massachusetts Institute of Technology.

Julia Hu is the co-founder and CEO of Lark, an A.I. Cardiometabolic and GLP1 Cost Containment Platform providing scalable, compassionate chronic disease management. Inspired by her own health challenges, she is happy that Lark has treated 2.5 million patients for their health plan, employer, and PBM partners. Julia was named Inc's 30 Under 30 and inducted into UCSF Health's Hall of Fame and named an EY Entrepreneurial Winning Woman. Previously, she led a global startup incubator and was an Entrepreneur-in-Residence at Stanford’s StartX. Julia has served on several nonprofits- Silicon Valley Leadership Group, Council for Diabetes Prevention, and was faculty at Singularity U.

Dr. Kesselheim brings to Transformation Capital more than 20 years of investing and clinical experience and has a demonstrated history of identifying compelling companies and helping them realize continued innovation, growth and successful exits. Dr. Kesselheim co-founded Transformation Capital’s predecessor management company with Mr. Cozzens and led the investment in 12 companies across Funds I – III, including Vera Whole Health (acquired by CD&R and then minority recapitalization led by Elevance – now called Mosaic), Scientist, Aktana, Protenus, Groups, Panalgo (acquired by Norstella), CapitalRx (minority recapitalization led by Prime Therapeutics), CareRev, Thriveworks, LightForce Orthodontics, Jeenie, and Nira Medical. Previously, Dr. Kesselheim was at Bain Capital Ventures, where he led BCV’s digital health practice as part of an $850 million multi-sector fund. Dr. Kesselheim became a Partner of Bain Capital Ventures in January 2014, having previously served as an Associate and Principal after joining that firm in July 2008 after his residency at Mass General Hospital. During his time at Bain Capital Ventures, Dr. Kesselheim was involved in multiple high growth investments including: Apixio (Board Director; acquired by Centene), Remedy Partners (Board Observer; acquired by New Mountain Capital in 2019, merged with Signify Health and then had an IPO in 2021), ABILITY Network (Board Director after being Board Observer; acquired by Summit Partners in 2014 and then acquired by Inovalon in 2018), MedHOK (Board Observer; acquired by Hearst in 2016), National Cardiovascular Partners (Board Observer; acquired by Fresenius in 2014), and Liazon (Board Observer, acquired by Towers Watson in 2014). Prior to his investing career, Dr. Kesselheim completed his residency in Internal Medicine at Massachusetts General Hospital. As a resident physician, Dr. Kesselheim oversaw a primary care panel of 300 patients and directed care teams within the hospital’s general medical wards and the medical intensive care unit. Dr. Kesselheim graduated from Harvard College summa cum laude and Phi Beta Kappa with a degree in Biochemical Sciences. He also received an MD from Harvard Medical School and an MBA from Harvard Business School where he was a Baker Scholar. Investment Experience: Vera Whole Health (acquired by CD&R), Scientist, Aktana, Protenus, Groups, Panalgo (acquired by Norstella), CapitalRx (minority recapitalization led by Prime Therapeutics), CareRev, Thriveworks, LightForce Orthodontics, Jeenie, Nira Medical.

Dr. Stephen K. Klasko is a radical healthcare innovator who thrives at the intersection of Silicon Valley and medical academia. As the former President and CEO who transformed Thomas Jefferson University & Jefferson Health from a $1.8 billion regional player into a $10 billion healthcare empire, he pioneered the audacious merger between a health sciences university and a nationally ranked design school, proving that healthcare's future lies in creativity as well as clinical excellence. Currently serving as Executive in Residence at General Catalyst, the world's largest venture capital investor in generative AI and large language models, Klasko orchestrates global resources for digital healthcare transformation while also serving as North American Ambassador to Sheba Medical Center, Israel's most extensive health system. His board leadership spans from NYSE's Teleflex (as Lead Independent Director of the $12 billion medical device giant) to NASDAQ's DocGo (as Board Chair), plus a portfolio of cutting-edge startups, including Globo, Amplify MD, CraniUs, Paradigm, Oova, and Agentis, that are reimagining healthcare delivery. A recent Presidential appointee to the National Board of Education Sciences and former Dean of two medical colleges (University of South Florida and Drexel), Klasko has spent decades dismantling the artificial barriers between high-tech innovation and high-touch care. His visionary leadership earned him recognition as #2 in Modern Healthcare's "100 Most Influential People in Healthcare," tied with industry titans Tim Cook and Jeff Bezos, and #21 in Fast Company's "100 Most Creative People in Business." As a prolific author whose works range from serious healthcare manifestos to satirical children's books, Klasko's intellectual influence extends far beyond the written page. His groundbreaking "UnHealthcare: A Manifesto for Health Assurance" (2021), co-authored with General Catalyst's Hemant Taneja, not only diagnosed healthcare's problems but also sparked a movement that directly inspired General Catalyst's health assurance fund and led to the creation of HATCO (Health Assurance Transformation Company). His upcoming "Hitchhiker's Guide to the Healthcare Galaxy" (2026) promises to be his most provocative yet, a time-traveling romp through healthcare's future that demonstrates how the collision of radically different universes can fix America's fractured system. His recent "Patient No Longer: How YOU Can Lead the Consumer Revolution in Healthcare" (2025) and "Feelin' Alright: How the Message in the Music Can Make Healthcare Healthier" (2023) showcase his ability to find profound insights in unexpected places. But perhaps most intriguingly, this MD/MBA/honorary doctorate holder who chairs the CEO Council of the American Cancer Society and advises companies like Hippocratic AI also moonlights as an active DJ spinning sets from Miami to San Francisco, a fitting metaphor for someone who has made a career of mixing seemingly incompatible worlds into something entirely new. Whether he's piloting planes, running marathons, or scuba diving, Klasko approaches everything with the same philosophy that has defined his healthcare revolution: the most interesting solutions emerge when you refuse to accept that different worlds can't work together. Dr. Klasko holds an MD from Hahnemann University, an MBA from the Wharton School, and an honorary doctorate from Fairleigh Dickinson University.

Nickolas Mark is a highly accomplished healthcare industry leader who is deeply committed to addressing the most pressing challenges in healthcare. As the Co-Founder and Managing Partner of Intermountain Ventures, a healthcare venture capital fund, Nickolas collaborates with early-stage pioneers, creative entrepreneurs, and mission-driven organizations to drive innovation and transformation in the industry. Prior to co-founding Intermountain Ventures, Nickolas held senior leadership positions at a global investment firm with approximately $50 billion in assets under management. He also worked as a senior advisor at leading consulting firms where he focused on executing innovation and growth-related initiatives for Fortune 500 companies and global organizations. Nickolas has a relentless focus on making a meaningful, measurable, and positive impact in the healthcare industry. He is dedicated to partnering with innovative pioneers, creative entrepreneurs, and mission-driven organizations to drive change and address the biggest challenges in healthcare.

Tarun Mehra is a Partner at Microsoft, where he leads Strategy & Partnerships for Healthcare Industry Segment and for Microsoft Dragon Copilot. In this role, he drives strategic growth initiatives, fosters innovation, and forges transformative partnerships across the healthcare ecosystem. Tarun is deeply committed to helping healthcare organizations address critical industry challenges through cutting edge technologies including Microsoft's Cloud, Data, Gen AI, and Dragon Copilot platforms. He also serves as a senior advisor to M12 (Microsoft’s venture fund) and 'Microsoft for Startups', supporting healthcare-related investments and innovation ecosystem growth. Tarun also represents the firm on the LPACs of select early-stage healthcare funds. Previously, he was VP of Strategy, M&A, and Partnerships at Nuance Communications (before Microsoft acquisition), where he helped expand its clinical documentation portfolio, including the Dragon and DAX Copilot platforms. Tarun also brings nearly two decades of experience in senior strategy consulting roles, advising Fortune 500 companies and private equity firms in the healthcare and technology sectors. He previously served as an Associate Partner at Monitor Group (now part of Deloitte), where he worked with large health systems and payers on growth strategy, M&A, and innovation. He also led the healthcare consulting practice at Fuld & Company, where he founded and ran a new business line as CEO before leading it through a strategic exit. He began his career in technology and product development before transitioning into strategy following his MBA. He holds a B.Tech. in Mechanical Engineering from IIT Delhi and an MBA from IIM Indore.

Mark Michalski, M.D., is Chief Information Officer and joined the Firm in 2024. As CIO, Mark leads the Deerfield Intelligence team and is responsible for overseeing the expansion and launch of new software and AI enabled products and services and supporting related capabilities for portfolio companies. Dr. Michalski concurrently serves as Chief Executive Officer at Ascertain, a technology company specializing in AI-driven automation solutions for healthcare enterprises. Before this, Dr. Michalski led strategic business development for Amazon’s healthcare and life sciences business units. He also served as Founding Executive Director of Mass General Brigham AI (formerly the Center for Clinical Data Science). Earlier in his career, Dr. Michalski served as President and Chief Medical Officer at Butterfly Network (NYSE: BFLY) and Chief Medical Officer at Hyperfine Research (NASDAQ: HYPR). Dr. Michalski holds a B.S. in Cybernetics from University of California, Los Angeles, a M.D. from Stanford University School of Medicine, and completed residency training at Yale New Haven Hospital. Dr. Michalski is certified by the American Board of Radiology and holds a medical license in New York State.

As a Partner and Executive Director at CVS Health Ventures, I lead the early and mid-stage investment program in digital health start-ups. I aim to make an impact through bridging the gap between CVS Health and the start-up ecosystem, and driving meaningful partnerships that bring new digital experiences to users in healthcare. I have led investments and partnership execution in areas spanning virtual specialty care, women's health, behavioral health, digital therapeutics, and more. I am passionate about digital innovation in healthcare and its potential to improve lives and outcomes.

Candace Richardson is a Partner at General Catalyst and leads the firm’s healthcare services investment strategy. She backs transformative companies across all stages, with a focus on improving access, quality, and affordability across the care journey. She is especially focused on AI and policy as critical tools for building large, durable platforms in the space. She has invested in and or serves on the boards of companies including Devoted Health, Cityblock Health, Maven Clinic, Harbor Health, Homeward Health, Chamber Cardio, Zarminali, Welltheory, Instride Health, Eleanor, and Equip.

Dr. Said is the Founder and CEO of Outcomes4Me, a health technology company focused on empowering cancer patients with personalized, evidence-based navigation and improving outcomes through better access to innovation. Prior to founding Outcomes4Me, she was Senior Vice President of Global Market Access & Policy at Novartis Pharmaceuticals and Vice President of Strategy & External Innovation at Sanofi. Dr. Said is a strong advocate for life sciences innovation and serves on the Board of Directors of Transgene, Pieris Pharmaceuticals, and Home Biosciences. She was a founding member of the Boston Consulting Group Strategy Institute. Dr. Said trained at the Massachusetts Institute of Technology, earning dual degrees in Biology and Electrical Engineering and Computer Science with a minor in Economics. She also holds a Master of Science in Toxicology, a Master of Engineering in Electrical Engineering, and Computer Science, and a Doctor of Science in Electrical Engineering, Computer Science, and Systems Biology, all from MIT.

Over 20 years of experience in biotech commercial strategy; the last 5 years leading strategic partnerships for Biogen North America with a goal to drive market development through non-traditional collaborations across the healthcare ecosystem.

Michelle Snyder brings over 25 years’ healthcare industry experience in marketing, business development, strategic planning, public policy, and general management. Prior to joining McKesson Ventures, she was Chief Marketing Officer at Welltok as well as an early executive at Epocrates, where she worked for over a decade to build the company into one of the most recognized brands among clinicians. Her MV investments include CancerIQ, Galileo, Inbound Health, Reimagine Care, and RxVantage. Michelle has also served as an Executive-in-Residence at InterWest Partners, investing in digital health companies and advising portfolio companies. In addition, she has held consulting and policy positions at The Wilkerson Group, the Lewin Group and the Georgetown Center for Health Policy Studies. Michelle earned her M.B.A. at the Kellogg School of Management at Northwestern University and her B.A. from Carleton College. Though she’s been in the Bay Area for over 20 years, she still dons green and gold and wears her Cheesehead proudly on Sundays.

Ben is an Operating Partner on the healthcare team at General Atlantic and serves on the boards of CoPilot IQ, Equality Health, and Eventus Whole Health, where he leads day-to-day operations as Executive Chairman. Prior to joining General Atlantic, Ben was Vice President of Enterprise Strategy at Humana where he was responsible for long-term growth and resource allocation. While there he was instrumental in the creation of a new behavioral health company, Author Health, and launched the company’s integrated, value-based care delivery strategy. He also led a $1B+ growth and productivity initiative that led to reduced operating expenses across the enterprise and industry leading market share growth. Previously Ben was at CVS Health / Aetna where he was Vice President and General Manager over the analytics product and consumer facing technology businesses. While there he created a new joint venture with Apple and managed a team of several hundred engineers and data scientists. Prior to Aetna, Ben co-founded and successfully launched Walmart’s first health service delivery business, the Walmart Care Clinic, as well as joint ventures with McKesson and Quest Diagnostics. Before joining Walmart, Ben led the healthcare practice at the Clayton Christensen Institute for Disruptive Innovation. Ben earned a bachelor’s degree in Management from Brigham Young University and an MBA from Harvard Business School.